• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Keep Buying Pot Stocks; Weed Isn't Going Away

Selloffs like the one in marijuana stocks present entry points, if this is your cup of tea.
By STEPHEN GUILFOYLE
Jan 5, 2018 Updated Jan 05, 2018 | 07:57 AM EST
Stocks quotes in this article: MJX, SMG, KSHB, CRBP, INTC, AMD, NVDA, AZZ, CALM, STZ, GBX

"That's how you win -- pitching and defense." -- Derek Jeter

Another Toke

Let's get one thing straight. I don't give a rat's tail if the recreational use of marijuana is legal or not. It's not part of my world. That is, unless I can profit from it. Then I care a great deal. Medical use? Well, that I do care about, and I feel that to deny those suffering is truly immoral. After covering the impact of the legalization of recreational use of pot in the state of California just last week, the subject is back in the news.

Headlines circulated throughout the business world on Thursday that the U.S. Justice Department plans to rescind the Obama-era Cole Memo. This memo, that maybe you never heard of, is where the Federal government backs off from its approach as far as enforcement goes in states that have legalized the use of this drug. To date, eight states and the District of Columbia have legalized recreational use. Another 21 states have already legalized medical use. The states of Massachusetts and Maine are also close to legalization.

What do the people think? According to Gallup, 64% of American adults want marijuana legalized. What do traders think? Well, after this move by Attorney General Jeff Sessions, the ETFMG Alternative Harvest ETF (MJX) tumbled more than 6% on the day. Remember those stocks that I profiled last Sunday? I said that Scotts Miracle Grow (SMG) would interest me around $104, and Kush Bottles (KSHB) around $3.25? Well. I was banging around TV studios on Thursday. I missed those opportunities, but both of those names traded below those levels and rebounded by day's end, still well off from Wednesday's closing prices.

My favored play in last Friday's note was the biotech Corbus Pharma (CRBP) . This stock fell 1.7% on Thursday, which really made it an outperformer, thanks to the fact that this is not a recreational play at all. This stock remains above $8 support and below $8.60 resistance. Remember, we covered that. I still think you can get two bucks on this one, should it hold $8.60 at some point. The risk is, like with all revenue-losing small-caps, when the bills come due, dilution might become reality. This particular company is playing the game with almost no debt load, however, so I think (no promises) that you have some time there.

One More Thing

Yeah, this matters. Enforcement is likely to be left to state-level attorney generals. Not only are local governments that have already legalized the use of pot less likely to crack down on those buying and selling, but what AG would go after commerce in a tax-paying industry? Not a smart one. My conclusion? The trend is clear. The winners I choose may or may not be correct, but the space is not going away, and there will be winners. Selloffs like this present entry points if this is your cup of tea. Bigger headline than story, in my opinion.

James Bond

Meltdown and Spectre. Oh, my. I remember when Spectre was simply what they called the bad guys in the old James Bond movies. First these vulnerabilities, particularly Meltdown, were problems for the semiconductor producing giant Intel (INTC) . Spectre is apparently a broader problem. Intel sold off on Wednesday, while most of the industry had a nice day. Advanced Micro Devices (AMD) , by the way, roared that day.

Then came disputed headlines that potential patches would slow down performance. INTC sold off. AMD roared. Intel executive Steve Smith spoke publicly: "We don't expect any financial implications around Intel's products". Huzzah. The stock then sold off again, then rallied into Thursday's close. Still seriously lower for a second straight day. INTC is down small in overnight trading.

AMD has come out and told you that their chips have "near zero" risk. AMD shares are up 17.9% year to date. Sarge... c'mon, it's like, January 5th. No kidding! Over the same time span, INTC is down 3.75% and Nvidia (NVDA) is up 10.4% because, well, it is NVDA.

A lot was made in the media over CEO Brian Krzanich's sale of a portion of his shares, but that sale had been scheduled way ahead of time, and I do not see a negative story there. Another story broke stating that several tech firms were notified of these vulnerabilities as early as last June. Is that negative? Hmm. I just don't know. I am a trader, and an investor. I am not a tech guy, What I do know, is how to defend myself.

Defending What's Mine

I am long Intel, like much of the planet. Like many home-gamers. I pounded the table last year on behalf of this name. I added to the position more than once. This name has been good to me, among my book's top performing names for 2017. I suspect the same is true for many of you.

My belief is that when you are sitting on giant gains in a name such as this, and especially when that name heads into a period of uncertainty, one must take some action. Sure, you could just buy put options as insurance. I hate buying options. I have told you that many times. All that does, much of the time, is increase your effective average point of entry. Who the heck needs that?

You could throw a stop-loss order out there. That is a somewhat effective strategy, but is not creative, and smacks of fear. Just don't forget it's out there. A trailing stop almost insures that some creepy algorithm will identify your order, and make you feel like you have just been picked off. I will tell you what I did, and what actions I am likely to take after looking at the chart.

First, I took 30% off of the top at the first sign of possibly sustained trouble. I put that money into Macy's M for now, as I liked its same store sales and the stock reacted irrationally. That is not, however, part of this story. On to the chart.

Chart of the Day: Protecting Intel 

Alright gang, this is where we buckle our chinstraps and earn our keep. Money Flow looks positive. That's the only nice-looking item on this chart. Throw it out.

Moving average convergence divergence MACD? Just experienced a bearish cross-over. On top of that, the nine-day exponential moving average (EMA) now sports a minus sign. Relative strength is rapidly deteriorating.

See the Pitchfork? Was working well. Looks broken now. 50-day simple moving average (SMA)? Broken too. News events will do that to you. You know what looks like it's not broken? Those blue Fibonacci levels that I threw up there.

See that intra-day rebound that INTC experienced on Thursday? Right at (or close enough to) a 38.2% retracement of the move from the August low through the December high. Conclusion here? $42.50 could be the gateway that allows for considerably lower prices should these stories persist, and the level crack.

Environment Provided

Intel is expected to report fourth-quarter earnings after the closing bell on Thursday, Jan. 25. Wall Street consensus is looking for about $0.86 on roughly $16.3 billion. The firm earned EPS of $1.01 for the third quarter, on expectations of just $0.80. That was on revenue of $16.1 billion. The actual data here will likely matter less than how the firm presents itself and what they project for 2018. The already mentioned issues will be front and center.

Adaptation and Excellence

Knowing this, we will walk through an example of how a retail investor might protect his or her long position. Let's say the investor owns 100 shares for the sake of convenience. First, we are going to marry a put to that long. Sarge! I thought you said you hated buying options? I do. Hear me out. The chart tells us that $42.50 is possibly a breaking point. Jan. 26 (one day after earnings) $42.50 puts went out last night at $0.64. So, you are adding $0.64 to your average price if you do this alone, but it does protect you for three weeks.

Now, we are going to cover the same 100 shares with a call option. We will sell (write) the Jan. 26 $46.50 calls. They went out at $0.66 last night. This replaces the money that you spent on the puts. You have only lost commission on this transaction based on these prices. Now you have downside protection for three weeks, but have limited your profit for those same three weeks that happen to cover a quarterly earnings release. What do you care about to a greater degree right now? If you have to sell the shares at $46.50, that is still darned close to a millennial high.

Sarge's Trading Levels

These are my levels to watch today for where I think that the S&P 500, and the Russell 2000 might either pause or turn.

SPX: 2743, 2736, 2729, 2723, 2715, 2709
RUT: 1569, 1562, 1557, 1550, 1543, 1535

Today's Earnings Highlights (Consensus EPS Expectations)

Before the Open: (AZZ) ($0.58), (CALM) ($0.70), (STZ) ($1.88), (GBX) ($0.92).

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was long INTC, NVDA, AMD, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Technology | Markets | How-to | Options | Stocks

More from Healthcare

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Here's Why Eli Lilly Broke to the Upside

Bruce Kamich
Jan 11, 2021 1:00 PM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login